Risk of new vertebral fracture was reduced among women int he romosozumab-to-alendronate group vs those who took alendronate alone.
Both intensity of physical activity and time spent active can explain variability in femoral neck BMD in people with class III obesity.
A femoral stress index assessment evaluates fracture risk in children as effectively as femoral and total body bone mineral density.
In a double-blind multicenter study, researchers examined the safety and efficacy of burosumab for X-linked hypophosphatemia.
Patients treated with zoledronic acid vs oral bisphosphonates had higher risk for heart failure and arrhythmias.
More than 75% of patients in the treatment group experienced a decrease in bone marrow edema.
Intermittent hypoxia in obstructive sleep apnea was found to decrease the chances of bone health decline in menopausal women.
Both anxiety and depression scores are associated with low BMD.
It has been previously reported that parathyroidectomy can reverse cognitive dysfunction associated with primary hyperparathyroidism.
Endocrinology Advisor Articles
- Imaging Studies in Hypothyroidism Evaluation Linked to Unnecessary Risks
- Insulin Glargine Associated With Breast Cancer Risk in T2D
- Transoral Endoscopic Thyroidectomy Vestibular Approach: Safety and Outcomes
- Once-Weekly Omarigliptin Improves Glycemic Control in Type 2 Diabetes
- Improving Vascular Function in Pediatric T1D With Metformin
- Update on Vitamin D and Calcium Supplements for Reducing Fracture Risk
- Lower Risk for SGLT2i-Associated Genitourinary Infection With DPP-4i
- Severe Hypoglycemia Associated With Increased Mortality Risk in T2D
- Efficacy of CGM in Preterm Infants of Mothers With Diabetes
- SSRIs and SNRIs Linked to Type 2 Diabetes in Children, Adolescents
- Increased Risk of Diabetes, Post-Diabetes Pneumonia for Patients With COPD
- Pancreatic Exocrine Dysfunction Occurs After Islet Autoimmunity in T1D
- T2D in African American Women Ups ER-negative Breast Cancer Risk
- High-Sensitivity CRP and LDL-C Predictive of Subsequent MACE in T2D
- Risks Associated With Denosumab Discontinuation